Peter Buhl Jensen

Biography

Buhl Jensen, born 1955, is CEO of Oncology Venture Sweden AB (publ) since 2015, and since 2012, CEO of the wholly owned subsidiary Oncology Venture ApS. Buhl Jensen has a strong combination of commercial experience and expertise in the field of oncology. Buhl Jensen has founded and was previously CEO of TopoTarget A/S. Buhl Jensen was instrumental in TopoTarget’s stock exchange listing in 2005 and secured EMA and FDA approval of the company’s first product, Savene©/Totect©. Buhl Jensen is also behind the development of the pharmaceutical drug Belinostat, which was approved by the FDA in the summer of 2014. Buhl Jensen has managerial experience from TopoTarget, where he managed approx. 140 employees and Aalborg Hospital where he was a senior consultant at the Department of Oncology and led approx. 280 employees. Owns 80%* of Buhl Krone Holding ApS** which owns 1,000,000 shares of the Company. Does not hold any warrants in the Company. Member of several boards in Oncology Biotech companies. Since 2010 Chairman of WntResearch.The remaining 20% is owned by Ulla Hald Buhl, who is Peter Buhl Jensen’s wife and a member of the Board of Oncology Venture.The same corporate registration number as Buhl Oncology ApS.

Research Interest

Buhl Jensen is also behind the development of the pharmaceutical drug Belinostat, which was approved by the FDA in the summer of 2014. Buhl Jensen has managerial experience from TopoTarget, where he managed approx. 140 employees and Aalborg Hospital where he was a senior consultant at the Department of Oncology and led approx. 280 employees.